|
Dr Reddys Laboratories allots 9,165 equity shares under ESOS> |
|
Dr Reddy’s Lab arm inks pact with Immutep SAS for novel cancer immunotherapy> |
|
Dr Reddys Laboratories Ltd up for five straight sessions> |
|
Dr Reddys Lab gains after securing EC nod for AVT03> |
|
Dr. Reddy's receives EC marketing authorization for AVT03 (denosumab)> |
|
Dr Reddys Laboratories Ltd up for fifth session> |
|
Dr Reddys Laboratories allots 7,430 equity shares under ESOS> |
|
Dr. Reddy’s, Shaily Engineering tumble after delay in Semaglutide approval> |
|
Dr Reddy's Laboratories consolidated net profit rises 7.28% in the September 2025 quarter> |
|
Dr Reddys Lab Q2 PAT jumps 14% YoY to Rs 1,437 cr> |